Adaptive Biotechnologies develops clinical products and diagnostic services by harnessing the adaptive immune system's biology through proprietary sequencing, computational biology, and machine learning to create actionable clinical insights. The company operates two main business segments: the MRD business, which offers clonoSEQ, an FDA-authorized diagnostic test for detecting minimal residual disease in lymphoid malignancies with industry-leading sensitivity and broad reimbursement coverage, and the Immune Medicine business, which provides immune receptor sequencing services, proprietary dataset licensing, and target discovery capabilities leveraging the company's ability to characterize T cell and B cell receptors at scale. The company generates revenue from clinical diagnostic testing and pharma partnerships supporting biopharmaceutical drug development, with growing penetration across multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin's lymphomas.